Crowell & Moring advises Colby Pharmaceutical in exclusive licensing agreement with MannKind
Crowell & Moring LLP aided San Jose-based Colby Pharmaceutical Co. in an exclusive licensing agreement with MannKind Corp. to commercialize and develop MannKind's cancer immunotherapy program, MKC1106. Colby will pay Valencia-based MannKind $140 million, to be split between an upfront payment and future payme...
To continue reading, please subscribe.
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In